在意大利，接受过口服 HIV 预防药物（PrEP）的男男性行为者队列中，卡替拉韦长效注射制剂具有较高的转换意愿。
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.
机构信息
Vita-Salute San Raffaele University, Via Stamira D'Ancona 20, Milano, 20127, Italy.
Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy.
出版信息
AIDS Behav. 2024 Mar;28(3):907-911. doi: 10.1007/s10461-023-04197-8. Epub 2023 Oct 4.
Aim was to investigate the propensity to switch to long-acting injectable HIV pre-exposure prophylaxis (PrEP) with cabotegravir among oral PrEP-experienced men who have sex with men. Out of 377 PrEP users, 325 (86.2%) were interested (would like = 210) or considering (would consider = 115) switch to long-acting PrEP. At multivariable analysis, the odds ratio of interest in long-acting PrEP in non-adherent vs. adherent individuals to oral PrEP was 5.03 (95%CI = 1.73-14.61,p = 0.003) and of consideration 1.63 (95%CI = 0.51-5.23,p = 0.410). We observed very high propensity to switch to long-acting PrEP, particularly among non-adherent users. Rapid availability of long-acting PrEP might address unmet needs of PrEP users in Italy.
目的在于调查有过口服暴露前预防（PrEP）用药史的男男性行为者（MSM）对改用长效注射型 HIV 暴露前预防（PrEP）药物卡替拉韦的倾向。在 377 名 PrEP 用户中，325 名（86.2%）表示有兴趣（愿意=210 人）或考虑（会考虑=115 人）改用长效 PrEP。多变量分析显示，与口服 PrEP 依从性个体相比，不依从性个体对长效 PrEP 的兴趣的优势比为 5.03（95%CI=1.73-14.61，p=0.003），考虑的优势比为 1.63（95%CI=0.51-5.23，p=0.410）。我们观察到改用长效 PrEP 的意愿非常高，尤其是在不依从性使用者中。长效 PrEP 的快速供应可能会满足意大利 PrEP 用户的未满足需求。
Zotero 插件